This event was held for customers who purchased Kajiwara's confectionery machine.

Once again this year, the managing director Jens Kallfass was able to honor jubilees at the Christmas party.

The current situation clearly shows how important packaging in general and film packaging in particular are and not only

2.Production time reduction and quality improvement brought by α mechanism Production time is greatly reduced, quality i

Germ-free and virus-free mould dehumidification with DMSterile Programme expansion for aseptic production Kundl (Austria), 21.04.2020: For food and pharmaceutical manufacturers, sterilising the production areas is a common practice. When producing packaging for the same manufacturers, there is additional demand for sterile and low-particle plastic production. Blue Air Systems has developed a new product for this sector: the proven DMS (Dry Mould System) dehumidifiers are now available in the germ and virus-free version, DMSterile. DMSterile directly generates a germ and virus-free atmosphere during mould dehumidification. The end products, such as pharmaceutical containers, PET pre-forms or sealing caps, come into contact exclusively with sterile air during production within the partitioning. Advantages of germ and virus-free production Micro-organisms thrive where moisture and heat are present. Both conditions are often found in production halls. In addition, outdated or irregularly maintained filters of air conditioning systems, ventilation systems and even production machines facilitate the multiplication of germs and viruses. Aseptic production with DMSterile ensures an optimum environment for manufacturing plastic products and avoids costly after-care. Aseptic dehumidification with Clean Blue Air Aseptic dehumidification with the Clean Blue Air system provides sterile air quality without any micro-organisms in the production process. Together with the existing dehumidification technology, DMSterile improves the quality of the end product. With DMS dehumidification, the energy requirement of the production process is reduced by up to 80% due to the known energy savings, while increasing the quality level and output. The manufacturer Blue Air Systems provides further information and the opportunity to make a configuration query based on the desired process air volumes at clean@blue-air.at. Contact Blue Air Systems GmbH Achenfeldweg 8 A-6250 Kundl/Tyrol Austria Tel.: +43 (0) 5338 211 71-0 Fax: +43 (0) 5338 211 71-20 Email: info@blue-air.at Website: www.blue-air.at Managing Director: Bernhard Stipsits Blue Air Systems at a glance Blue Air Systems GmbH, founded in 2010 and based in Kundl/Tyrol (Austria), supplies the plastics processing industry with innovative technology for energy saving. Blue Air Systems, the leading innovator, has over 30 years of experience with effective, air-based process solutions for plastics technology. In the core field of air-conditioning technology, Blue Air Systems stands for solutions with cryogenic or dry air for energy-efficient processing for the plastics industry and other industries. Blue Air Systems develops not only high-quality, but above all safe and easy-to-use solutions that require as little energy and maintenance as possible. The company's product-supporting services include application and service-oriented advice for processors. The main products and applications in air conditioning technology include systems for mould cavity dehumidification (BAS-MSP and BAS-DMS series) and internal product cooling (BAS-CAC series) for effective cooling of blow-moulded parts using extremely cold and dry compressed air (-35ºC) (process volumes 120 to 540 Nm³/h). BAS-CAC significantly reduces material stress and cooling times by up to 50%. In the field of material handling, Blue Air Systems offers a comprehensive range of compressed air-based resin dryers for efficient and gentle material processing (RDM, RDX and RDL series) based on the Venturi principle. The use of the compressed air available from the company is a very economical alternative to conventional drying systems, such as adsorption dryers. The compressed air technology with process volumes from 0.5 to 1,000 litres guarantees the best drying results - grain by grain, with minimum operating costs and virtually maintenance-free production. A worldwide network of sales and service centres through representatives ensures optimum support for users and long-term value retention of the solutions used. Constant growth, references in more than 35 countries worldwide, innovative technologies and a high quality make Blue Air Systems a globally established and reliable partner for the plastics industry. Blue Air Systems has 15 employees (2020) and an export rate of about 98%.

Research and development is very important at Sappi, the result of which is the development of an exceptional level of e

Cold storage retrofit challenges Americold is a third-party logistics (3PL) company serving producers, retailers and fo

Amid increased demand from biologics and vaccines sectors, Company invests in additional die cutting and gluing machinery, expanding production capacity and allowing for expedited turnaround. Newark, NJ – Keystone Folding Box Co., a designer and manufacturer of paperboard packaging solutions, has incorporated new die cutting and gluing equipment into its production facility. The infrastructure investment increases the company’s production capacity of vial and syringe packaging by 25%, and accommodates shorter lead-times. Keystone offers a comprehensive line of secondary packaging systems for injectable pharmaceutical products. Available in a variety of tailored features and in both all-paperboard and plastic-hybrid formats, solutions are available for prefilled syringes, autoinjector pens, vials and ampoules, as well as combinations of these drug delivery formats. In particular, developments in the biologics and vaccines markets have led to heightened demand for custom packaging solutions for vial and prefilled syringe products. During the past six months, Keystone has seen significantly increased requests in these sectors, producing packaging solutions for pharma customers manufacturing monoclonal antibodies, vaccines, recombinant hormones/proteins, and cellular- and gene-based biologics, among other niches. According to a survey from Zion Market Research, the global vaccine market is expected to exceed $59 billion in 2020 – a figure that has nearly doubled in just six years. In the United States alone, the vaccines market is anticipated to reach $18 billion. The biologics market is growing at an even more exponential rate; according to current market reports, the global biologics market was valued at over $250 million in 2018, and is expected to exceed $625 million by 2026. To meet the building demand for packaging solutions in these sectors, Keystone’s secondary packaging collection meets a range of needs through options such as tamper evidence and child-resistance via reclosable locking mechanisms – all while ensuring parenteral product protection throughout the pharmaceutical supply chain. Solutions include: A line of Injectable Packs is suitable for prefilled syringes or autoinjector pens, and can be designed to include ancillary items like sterile wipes The InjectaSlide package incorporates a thermoformed tray that slides inside a carton and into a locked position; a lock release button must be pressed to unlock and slide the tray forward for easy access to each medicine dose. The Vial Pack line of cartons includes designs for packaging a single vial or ampoule, or as many pharmaceutical products as a program requires. “With injectable products made of glass or rigid plastic, protection is paramount.” said Ward Smith, Director of Marketing & Business Development at Keystone Folding Box Co.. “Secondary packaging must be designed and produced with the right materials to protect prefilled syringes, autoinjectors, vials and ampoules as they travel through the supply chain.” ### About Keystone Folding Box Co. While Keystone continues to be a leader in the manufacturing and design of paperboard packaging, they are also a design center and source for non-paperboard packaging components. To learn more about Keystone Folding Box Company, please contact Ward Smith at Keystone Folding Box Company, at (513) 871-4747, ward.smith@keyboxco.com or visit www.keyboxco.com. client: Keystone Folding Box Co. contact: Turchette Agency Christopher Dale (973) 227-8080, ext. 116 cdale@turchette.com Ward Smith Keystone Folding Box (513) 871-4747 ward.smith@keyboxco.com

Company also adds bottling and pouching equipment in anticipation of heightened demand. St. Louis, MO – Legacy Pharmaceutical Packaging, a contract packager serving the global pharmaceutical industry with bottling, blistering, pouching, unit-of-use, compliance and secondary packaging services, has purchased three high speed blistering and cartoning lines with serialization and aggregation capabilities from McKesson RxPak’s production facility in Memphis. The infrastructure acquisition nearly doubles Legacy’s total blister production capacity, which now stands at half a billion packs per year. In a separate equipment investment, this summer Legacy also will add an additional new high speed bottling line, bringing the contract packager’s bottling capacity to some 600 million units per year. Additionally, the company recently incorporated two new pouching machines to help meet growing demand for tablet and capsule filling applications. The expansion-minded moves come amid recent growth in both the Rx and OTC sectors, and in expectation of continued heightened demand per the company’s transition into a high-volume, one-stop shop providing turnkey product packaging straight through market delivery. Located in Memphis, McKesson RxPak is a division of McKesson Corp. and a leading provider of packaging products and services to manufacturers and retailers in the pharmaceutical industry. Michael Plumlee, Vice President of Sales “This will allow McKesson to focus on their portfolio expansion through their SKY Unit Dose Division.” “This infrastructure investment is a natural evolution of the expansion plans Legacy adopted several years ago, starting with a 100,000-square-foot expansion in 2017 that added both production capabilities and warehousing capacity providing a total of 300,000 square feet,” said David Spence, CEO of Legacy Pharmaceutical Packaging. “Considering both recent growth, and that we anticipate more US base production moving forward, this was the right time to continue in a way that makes Legacy an even more versatile, dynamic and turnkey packaging partner.” # # # About Legacy Pharmaceutical Packaging, LCC Legacy Pharmaceutical Packaging is a privately held contract pharmaceutical packaging company located in St. Louis, Missouri. Legacy is a full service pharma solution & medical device packaging provider servicing the branded, generic, government, wholesale and major retail markets. Legacy is registered with the FDA, VAWD accredited and licensed by the DEA to handle Schedule II-V drug products. Legacy Pharmaceutical Packaging is headquartered in St. Louis, MO. For more information, call (314) 813-1555 visit www.LegacyPackaging.com. client: Legacy Pharmaceutical Packaging, LLC contact: Christopher Dale Turchette Agency (973) 227-8080 ext. 116 cdale@turchette.com Brad Rayner Legacy Pharmaceutical Packaging, LLC Direct (314)549-8052 BRayner@legacypackaging.com

The three-year-long project brings together a diverse network of organizations and stakeholders throughout the value cha

The new Jowatherm® GROW product range of Jowat boasts hot melt adhesives with a very high content of renewable raw mater

In this solution, we provided a blister machine for chocolate product, the blister feeder contains a hopper and Pneumati

SafeTraces' saniDART™ is the first rapid solution for verifying sanitation effectiveness at a microbial level to receive

MADERA, CA, April 15, 2020 — JBT Corporation (NYSE: JBT), a leading technology solutions provider to the global food and

In 1977, we entered the pharmaceutical label industry with GMP-compliant roll tack labels.

The DigiSpense® 4000’s panel mount compact footprint, along with minimal side-to-side clearances, allows multiple contro

SUREFISH (2020-2023), financed with 2 million euros by the PRIMA (Partnership on Research and Innovation in the Mediterr

FRUIT LOGISTICA covers every single sector of the fresh produce business and provides a complete picture of the latest i

Crystal Lake, Illinois, April 3, 2020 - AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active packaging solutions, is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 mask). The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic. In this simple disinfecting process, the N95 mask and a Photo: N95 Mask Decontamination with ActivShieldTM by Aptar small strip of Aptar’s ActivShieldTM are placed inside any commonly available one-gallon plastic bag. The strip releases a controlled amount of chlorine dioxide inside the sealed bag to decontaminate the N95 mask. The process takes only three hours until the mask is ready to wear again. It can be performed on-site at the local hospital where the mask is being used. Aptar has submitted its safety and effectiveness data to the FDA for EUA review. The company is working to provide approximately four million ActivShield strips per week and is working to expand its production capacity with the intent to deliver ten million per week by the end of April. “We are extremely encouraged by the promising data generated so far and are eager to deliver this technology to the front line and support the fight against the pandemic,” said John Belfance, President of Aptar CSP Technologies. If the FDA approves the EUA, then ActivShield will immediately become available for this important use. Chlorine dioxide has been widely used as a disinfectant in different industries, including the paper industry, drinking water treatment, food processing, and medical equipment. Aptar’s delivery mechanism uses the disinfecting properties of chlorine dioxide in a controlled sustained release within a contained volume. This innovative patent pending technology can efficiently and effectively disinfect N95 masks used by healthcare workers and first responders. “Aptar’s technology provides a unique, simple, and effective way to help solve the critical problem of PPE shortages we’re currently facing,” said Stephan Tanda, Aptar President and CEO. “We are aiming to provide a solution that is not only fast, but it does not require special equipment or training, making it potentially accessible to the wider healthcare community. This could enable healthcare workers to retain and disinfect their own facemask, helping to maintain continued proper fit to their face.” About Aptar Aptar is a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active packaging solutions. Aptar uses insights, design, engineering and science to create dosing, dispensing and protective packaging technologies for the world’s leading brands, in turn making a meaningful difference in the lives, looks, health and homes of millions of people around the world. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. The company is headquartered in Crystal Lake, Illinois and has 14,000 dedicated employees in 20 countries. For more information, visit www.aptar.com. This press release contains forward-looking statements. Words such as “promising” or “working” and other similar expressions or future or conditional verbs such as “will” or “could” are intended to identify such forward-looking statements. Forward- looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: economic conditions worldwide; uncertainties related to the timing or outcome of product development; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-Ks and Form 10-Qs. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. # # # Product Contact: Corporate Contact: John Belfance Matt DellaMaria john.belfance@aptar.com matt.dellamaria@aptar.com 518-469-3358 815-479-5530